{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T17:36:55Z","timestamp":1773509815713,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,11,21]],"date-time":"2011-11-21T00:00:00Z","timestamp":1321833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> When xenotropic murine leukemia virus\u2013related virus (XMRV) was first reported in association with chronic fatigue syndrome, it was suggested that it might offer a risk to blood safety. Thus, the prevalence of the virus among blood donors and, if present, its transmissibility by transfusion need to be defined.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> Two populations of routine blood donor samples (1435 and 13,399) were obtained for prevalence evaluations; samples from a linked donor\u2010recipient repository were also evaluated. Samples were tested for the presence of antibodies to XMRV\u2010related recombinant antigens and\/or for XMRV RNA, using validated, high\u2010throughput systems.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> The presence of antibodies to XMRV could not be confirmed among a total of 17,249 blood donors or recipients (0%; 95% confidence interval [CI], 0%\u20100.017%); 1763 tested samples were nonreactive for XMRV RNA (0%; 95% CI, 0%\u20100.17%). Evidence of infection was absent from 109 recipients and 830 evaluable blood samples tested after transfusion of a total of 3741 blood components.<\/jats:p><jats:p><jats:bold>CONCLUSIONS:<\/jats:bold> XMRV and related murine leukemia virus (MLV) markers are not present among a large population of blood donors and evidence of transfusion transmission could not be detected. Thus, these viruses do not currently pose a threat to blood recipient safety and further actions relating to XMRV and MLV are not justified.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2011.03450.x","type":"journal-article","created":{"date-parts":[[2011,11,21]],"date-time":"2011-11-21T06:59:24Z","timestamp":1321858764000},"page":"298-306","source":"Crossref","is-referenced-by-count":17,"title":["Xenotropic murine leukemia virus\u2013related virus does not pose a risk to blood recipient safety"],"prefix":"10.1111","volume":"52","author":[{"given":"Roger Y.","family":"Dodd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Hackett Jr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Linnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerri","family":"Dorsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimian","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxing","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Schochetman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Carrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Krysztof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan L.","family":"Stramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,11,21]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0020025"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1179052"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1181349"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1006901107"},{"key":"e_1_2_8_6_2","unstructured":"American Association of Blood Banks.Published studies on XMRV and MLRV findings in human diseases and the general population.2011. [cited 2011 Nov 1]. Available from: URL:http:\/\/www.aabb.org\/resources\/bct\/eid\/Documents\/xmrvtable.pdf"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1208542"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1212182"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1205292"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1213841"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1204963"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02411-10"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03063.x"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.03012.x"},{"key":"e_1_2_8_15_2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1742-4690-7-68","article-title":"Characterization of antibodies elicited by XMRV infection and development of immunoassays useful for epidemiologic studies","volume":"7","author":"Qiu X","year":"2011","journal-title":"Retrovirology"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/854540"},{"key":"e_1_2_8_17_2","unstructured":"LinnenJ.Reported at US FDA Blood Products Advisory Committee Meeting. December 14 2010. [cited 2011 Nov 1]. Transcript available from: URL:http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/BloodProductsAdvisoryCommittee\/ucm239304.htm"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02386.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02486.x"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02932.x"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03267.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00693-11"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2011.03450.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2011.03450.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T12:29:27Z","timestamp":1697286567000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2011.03450.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,21]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1111\/j.1537-2995.2011.03450.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2011.03450.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,21]]}}}